Market Overview

UPDATE: Canaccord Genuity Upgrades InterMune to Buy on Esbriet EU Momentum

Related ITMN
4 Biotech Stocks Worth A Look Ahead Of FDA Approvals
3 Hot Biotech Stocks Hitting Highs

Canaccord Genuity raised its rating on InterMune (NASDAQ: ITMN) from Hold to Buy and increased its price target from $11 to $13.

Canaccord Genuity commented, "We've been waiting for a signal that ITMN could execute on marketing Esbriet – we think this could be it. We think the strength in Q3 sales may signal the start of a new ramp in pirfenidone sales, buoyed by upcoming French and Italian launches. We expect continued positive momentum in H1/13 as France and Italy could be better organized and more enthusiastic re pirfenidone than Germany. We are raising our target on increased adoption rates forecast in Q4/12, 2013 and 2014."

InterMune closed at $8.16 on Wednesday.

Posted-In: Canaccord GenuityAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings


Most Popular

Related Articles (ITMN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free